CVRx Inc Net Assets
CVRx Inc net assets. Based on the latest financial reports, CVRx Inc (CVRX) has net assets worth $19.95 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($92.28 Million) and total liabilities ($72.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of CVRx Inc to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $19.95 Million |
| % of Total Assets | 21.62% |
| Annual Growth Rate | N/A |
| 5-Year Change | -73.06% |
| 10-Year Change | N/A |
| Growth Volatility | 13.68 |
Net Assets of CVRx Inc (2019–2025)
Net assets of CVRx Inc from 2019 to 2025. This chart illustrates how CVRx Inc's net assets have evolved over time, based on quarterly financial data. See CVRx Inc (CVRX) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for CVRx Inc (2019–2025)
The table below shows the annual net assets of CVRx Inc from 2019 to 2025. For live market cap and overall valuation, see CVRx Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $39.32 Million | -44.66% |
| 2024-12-31 | $71.06 Million | -6.44% |
| 2023-12-31 | $75.95 Million | -30.44% |
| 2022-12-31 | $109.18 Million | -25.20% |
| 2021-12-31 | $145.96 Million | +149.77% |
| 2020-12-31 | $-293.24 Million | -5.09% |
| 2019-12-31 | $-279.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CVRx Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25308500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
CVRx Inc Net Assets Breakdown (December 2025)
CVRx Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $263.00K | 0.67% |
| Other Comprehensive Income | $-203.00K | -0.52% |
| Other Components | $629.92 Million | 1601.86% |
| Total Equity | $39.32 Million | 100.00% |
CVRx Inc Competitors by Market Cap
The table below lists competitors of CVRx Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Calgro M3 Holdings Ltd
JSE:CGR
|
$18.66 Million |
|
Brill Shoe Industries Ltd
TA:BRIL
|
$18.66 Million |
|
Hanchang Ind.Co.Ltd
KQ:079170
|
$18.68 Million |
|
Baylin Technologies Inc
TO:BYL
|
$18.68 Million |
|
Southern Fertilizer JSC
VN:SFG
|
$18.65 Million |
|
Cipta Selera Murni Pt
JK:CSMI
|
$18.65 Million |
|
Frontier Nuclear and Minerals Inc.
NASDAQ:FNUC
|
$18.64 Million |
|
ENERSIDE ENERGY EO -01
F:9O8
|
$18.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CVRx Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 71,055,000 to 39,324,000, a change of -31,731,000 (-44.7%).
- Net loss of 53,306,000 reduced equity.
- New share issuances of 8,974,000 increased equity.
- Other comprehensive income increased equity by 3,000.
- Other factors increased equity by 12,598,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-53.31 Million | -135.56% |
| Share Issuances | $8.97 Million | +22.82% |
| Other Comprehensive Income | $3.00K | +0.01% |
| Other Changes | $12.60 Million | +32.04% |
| Total Change | $- | -44.66% |
Book Value vs Market Value Analysis
This analysis compares CVRx Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.46x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-578.23 | $0.70 | x |
| 2020-12-31 | $-757.56 | $0.70 | x |
| 2021-12-31 | $7.04 | $0.70 | x |
| 2022-12-31 | $5.32 | $0.70 | x |
| 2023-12-31 | $3.66 | $0.70 | x |
| 2024-12-31 | $3.14 | $0.70 | x |
| 2025-12-31 | $1.51 | $0.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CVRx Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -135.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -94.10%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 2.66x
- Recent ROE (-135.56%) is below the historical average (-48.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -233.87% | 0.21x | 0.00x | $13.27 Million |
| 2020 | 0.00% | -233.09% | 0.09x | 0.00x | $15.21 Million |
| 2021 | -29.51% | -330.45% | 0.09x | 1.05x | $-57.67 Million |
| 2022 | -37.94% | -184.38% | 0.18x | 1.14x | $-52.35 Million |
| 2023 | -54.25% | -104.85% | 0.34x | 1.52x | $-48.79 Million |
| 2024 | -84.39% | -116.91% | 0.38x | 1.88x | $-67.07 Million |
| 2025 | -135.56% | -94.10% | 0.54x | 2.66x | $-57.24 Million |
Industry Comparison
This section compares CVRx Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,301,945,411
- Average return on equity (ROE) among peers: -40.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CVRx Inc (CVRX) | $19.95 Million | 0.00% | 3.63x | $18.65 Million |
| Abbott Laboratories (ABT) | $23.06 Billion | 24.91% | 1.28x | $190.04 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-132.02 Million | 0.00% | 0.00x | $3.53 Million |
| Aethlon Medical Inc (AEMD) | $-2.47 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.06 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.28 Million | -44.54% | 0.25x | $2.33 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $1.44 Million |
| Artivion Inc (AORT) | $7.30 Million | 9.59% | 0.70x | $980.00 Million |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $122.16 Million |
About CVRx Inc
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased … Read more